**7. Clinical Trials**

In recent years, along with thorough research, some of the principal active components of *T. impetiginosa* have been used in clinical research. For example, β-lapachone, mainly distributed in heartwood of *T. impetiginosa,* has entered into phase 2 clinical trials for treatment of squamous cell carcinoma, and 2-acetylnaphtho (2,3-β) furan-4,9-dione, also referred to as STAT3 inhibitor BBI608 (Napabucacin), was developed by Boston Biomedical Inc [14].
